|
||||||||
|
Coenzyme Q10 (CoQ10) is a compound found naturally in
the energy-producing center of the cell known as the mitochondria. CoQ10
is involved in the making of an important molecule known as ATP. ATP
serves as the cell's major energy source and drives a number of
biological processes including muscle contraction and the production of
protein. CoQ10 also works as an antioxidant.
Antioxidants are substances that scavenge free radicals, damaging compounds in the body that alter cell membranes, tamper with DNA, and even cause cell death. Free radicals occur naturally in the body, but environmental toxins (including ultraviolet light, radiation, cigarette smoking, and air pollution) can also increase the number of these damaging particles. Free radicals are believed to contribute to the aging process as well as the development of a number of health problems including heart disease and cancer. Antioxidants such as CoQ10 can neutralize free radicals and may reduce or even help prevent some of the damage they cause. Uses Heart Disease
Congestive Heart Failure (CHF)
High Blood Pressure
High Cholesterol
Diabetes Heart Damage caused by Chemotherapy
Heart Surgery
Breast Cancer
Periodontal (gum) Disease Other
Research in all of these areas is underway to determine whether CoQ10 can be safety and effectively used in people with these health problems.
Supporting Research Aberg F, Appelkvist EL, Broijersen A, et al. Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with combined hyperlipidaemia. Eur J Clin Invest. 1998;28:235-242. Al-Hasso. Coenzyme Q10: a review. Hosp Pharm. 2001;36(1):51-66. Alleva R, Scaraarmucci A, Mantera F, Bompandre S, Leoni L, Linarro GP. The protective role of ubiquinol—10 against formation of lipid hydroperoxdes in human seminal fluids. Mol Asp Med. 1997;18:221-228. Baggio E, Gandini R, Plancher AC, Passeri M, Carmosino G. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med. 1994;15(Suppl):s287-294. Chello M, Mastroroberto P, Romano R, et al. Protection by coenzyme Q10 from myocardial reperfusion injury during coronary artery bypass grafting. Ann Thorac Surg. 1994;58(5):1427-1432. Chopra RK, Goldman R, Sinatra ST, Bhagavan HN. Relative bioavailability of coenzyme Q10 formulations in human subjects. Int J Vitam Nutr Res. 1998;68:109-113. de Bustos F, Molina JA, Jimenez-Jimenz FJ, Garcia-Redondo A, Gomez-Escalonilla C, Porta-Etessam J, et al. Serum levels of coenzyme Q10 in patients with Alzheimer's disease. J Neural Transm. 2000;107(2):233-239. Eriksson JG. The effects of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus. Biofactors. 1999;9(2-4):315-318. Folkers K, Langsjoen P, Nara Y, et al. Biochemical deficiencies of coenzyme Q10 in HIV infection and exploratory treatment. Biochem Biophys Res Commun. 1988;153:888-896. Hanioka T, Tanaka M, Ojima M, Shizukuishi S, Folkers K. Effect of topical application of coenzyme Q10 on adult periodontitis. Mol Aspects Med. 1994;15 Suppl:s241-248. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health-System Pharm. 2000;57(13):1221-1227. Henriksen J, Andersen CB, Hother-Nielsen O, Vaag A, Mortensen SA, Beck-Nielsen H. Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well-being in patients with type 1 diabetes mellitus. Diabet Med. 1999; 16:312-8. Human JA, Ubbink JB, Jerling JJ, et al. The effect of simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolemia. Clin Chim Acta. 1997;263(1):67-77. Iarussi D, Auricchio U, Agretto A, et al. Protective effect of coenzyme Q on anthracylines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-hodgkin lymphoma. Molec Aspects Med. 1994;15(Suppl):S207-S212. Jolliet P, Simon N, Barre J, et al. Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences. Int J Clin Pharmacol Ther. 1998;36:506-509. Judy WV, Hall JH, Dugan W, et al. Coenzyme Q10 reduction of adriamycin cardiotoxicity. In: Folkes K, Yamamura Y, Eds. Biomedical and clinical aspects of coenzyme Q10, Vol. 4. Amsterdam: Elsevier. 1984:231-241. Kendler BS. Recent nutritional approaches to prevention and therpy of cardiovascular disease. Prog Cardiovasc Nurs. 1997;12(3):3-23. Khatta M, Alexander BS, Krichten CM, Fisher ML, Freudenberger R, Robinson SW et al. The effect of conenzyme Q10 in patients with congestive heart failure. Ann Int Med. 2000;132(8):636-640. Landbo C, Almdal TP. Drug interaction between warfarin and coenzyme Q10. Ugeskrift for Laeger. 1998;160(22):3226-3227. Langsjoen P, Langsjoen A. Overview of the use of CoQ10 in cardiovascular disease. BioFactors. 1999;9:273-284. Langsjoen P, Langsjoen A, Willis R, Folkers K. Treatment of Essential Hypertension with Coenzyme Q10. Molec Aspects Med. 1994;15:s265-s272. Lewin A, Loron M. The effect of coenzyme Q10 on sperm mobility and function. Mol Asp Med. 1997;18:213-219. Lockwood K, Moesgaard S, Folkers K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun. 1994;199(3):1504-1508. Lockwood K, Moesgaard S, Hanioka T, Folkers K. Apparent partial remission of breast cancer in "high risk" patients supplemented with nutritional antioxidants, essential fatty acids, and coenzyme Q10. Mol AspMed. 1994;15 Suppl:s231-s240. Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress in therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun. 1995;212(1):172-177. Marz W, Wieland H. HMG-CoA reducatse inhibition: anti-inflammatory effects beyond lipid lowering. Herz. 2000;25(6):117-25. Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA. July 21, 1998; 95:8892-8897. McCarty MF. Coenzyme Q versus hypertension: does CoQ decrease endothelial superoxide generation? Med Hypotheses. 1999;53:300-304. McCarty MF. Toward practical prevention of type 2 diabetes. Med Hypotheses. 2000;54(5):786-793. Miyake Y, Shouza A, Nishikawa M, Yonemoto T, Shimizu H, Omoto S, Hayakawa T, Inada M. Effect of treatment with 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. Arzneimittelforschung. 1999;49(4):324-329. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. 1997;18Suppl:S137-S144. Musumeci O, Naini A, Slonim AE, Skavin N, Hadjigeorgiou GL, Krawiecki N, et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurol. 2001;56(7):849-855. Niibori K, Yokoyama H, Crestanello JA, Whitman GJ. Acute administration of liposomal coenzyme Q10 increases myocardial tissue levels and improves tolerance to ischemia reperfusion injury. J Surg Res. 1998;79:141-145. Ostrowski RP. Effect of coenzyme Q(10) on biochemical and morphological changes in experimental ischemia in the rat brain. Brain Res Bull. 2000;53(4):399-407. Ott BR, Owens NJ. Complementary and alternative medicines for Alzheimer's disease. J Geriatr Psychiatry Neurol. 1998;11:163-173. Overvad K, Diamant B, Holm L, Holmer G, Mortensen SA, Stender S. Review coenzyme Q10 in health and disease. Eur J Clin Nut. 1999;53:764-770. Raitakari OT, McCredie RJ, Witting P, Griffiths KA, Letter J, Sullivan D, Stocker R, Celermajer DS. Coenzyme Q improves LDL resistance to ex vivo oxidation but does not enhance endothelial function in hypercholesterolemic young adults. Free Radic Biol Med. 2000;28(7):1100-1105. Serebruany VL, Ordonez JV, Herzog WR, et al. Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression. J Cardiovasc Pharmacol. 1997;29:16-22. Shils ME, Olson JA, Shike M, Ross AC. Modern Nutrition in Health and Disease. 9th ed. Baltimore, Md: Williams & Wilkins; 1999:90-92: 1377-1378. Shinozawa S, Kawasaki H, Gomita Y. [Effect of biological membrane stabilizing drugs (coenzyme Q10, dextran sulfate and reduced glutathione) on adriamycin (doxorubicin)-induced toxicity and microsomal lipid peroxidation in mice]. Gan To Kagaku Ryoho. 1996;23(1):93-98. Sinclair S. Male infertility: nutritional and environmental considerations. Alt Med Rev. 2000;5(1):28-37. Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J Hum Hypertens. 1999;13(3):203-208. Singh RB, Wander GS, Rastogi A, et al. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc Drugs Ther. 1998;12:347-353. Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet. 1994;344:1372-1373. Takahashi N, Iwasaka T, Sugiura T, et al. Effect of coenzyme Q10 on hemodynamic response to ocular timolol. J Cardiovasc Pharmacol. 1989;14:462-468. Torkos S. Drug-nutrient interactions: A focus on cholesterol-lowering agents. Int J Integrative Med. 2000;2(3):9-13. Tsukahara Y, Wakatsuki A, Okatani Y. Antioxidant role of endogenaous coenzyme Q against the iscemic and reperfusion-induced lipid peroxidation in fetal rat brain. Acta Obstet Gynecol Scand. 1999;78(8):669-674. Werbach M. Foundations of Nutritional Medicine. Tarzana, Calif: Third Line Press, Inc.; 1997:209. Wilkinson EG, Arnold RM, Folkers K. Treatment of periodontal and other soft tissue diseases in the oral cavity with coenzyme Q10. In: Folker K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q10, Vol 1. Elsevier/North-Holland Biomedical Press;Amsterdam, 1977:251-265. Witte KK, Clark AL, Cleland JG. Chronic heart failure and micronutrients. J Am Coll Cardiol. 2001;37(7):1765-1774. Zhou Q, Chan E. Accuracy of repeated blood sampling in rats: A new technique applied in pharmacokinetic/pharmacodynamic studies of the interaction between warfarin and Co-enzyme Q10. J Pharmacol Toxicol Methods. 1998;40(4):191-199. |
|||||||
|